Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical compositions containing taxane-cyclodextrin complexes, method of making and methods of use

A cyclodextrin and composition technology, which is applied in the field of taxane compound pharmaceutical preparations, can solve the problems of increased risk of cytotoxic compounds and the like

Active Publication Date: 2017-12-01
HUNAN JINZHUN MEDICAL TECH CO LTD
View PDF5 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Healthcare workers are at increased risk of exposure to these cytotoxic compounds as the powder must be reconstituted prior to use

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical compositions containing taxane-cyclodextrin complexes, method of making and methods of use
  • Pharmaceutical compositions containing taxane-cyclodextrin complexes, method of making and methods of use
  • Pharmaceutical compositions containing taxane-cyclodextrin complexes, method of making and methods of use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0069] Accelerated Aging Stability Study

[0070] The above liquid pharmaceutical composition comprising -10 mg / mL docetaxel was diluted and subjected to accelerated aging at 40°C for 11 days. Impurity levels specified by USP35 (United States Pharmacopeia 35) for taxane compositions were analyzed by HPLC at timed intervals. Stability was tested on day 0 at 6 hours. The impurity levels in the liquid pharmaceutical compositions were compared to the tolerable levels according to the USP35 standard. The results are shown in figure 1 middle. It can be seen that all impurities (Substances A-F) are well below the USP35 limit for the full 1 day period of accelerated aging. Furthermore, during the 11 days tested, there was no increase in the impurities present and no new impurities or degradation products were formed, indicating that the composition is chemically stable. The composition is also physically stable as no precipitate or haze is formed.

[0071] Furthermore, the con...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Pharmaceutical formulations for parenteral administration comprising taxane compounds complexed with cyclodextrins and polyethylene glycol, methods of making the pharmaceutical formulations and methods of treating cancer patients using the pharmaceutical formulations.

Description

field of invention [0001] The present disclosure relates to pharmaceutical formulations of taxane compounds for parenteral administration, methods of manufacturing the pharmaceutical formulations, and methods of using the pharmaceutical formulations to treat cancer patients. Background technique [0002] Taxanes are diterpenes widely used in chemotherapy. They were originally found in the yew plant (yew) and were first obtained from these natural sources. Several chemical synthesizers exist. Among the taxanes, the best known are paclitaxel (TAXOL) and the semi-synthetic analogue of paclitaxel, docetaxel (TAXOTERE). Taxanes exert their anticancer activity by inhibiting the depolymerization of tubulin in cells, thereby inhibiting mitosis. [0003] Parenteral administration by injection is the typical route of administration for taxanes. However, taxanes are substantially insoluble in water and other commonly used medical parenteral organic solvents, which presents challeng...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/337A61K9/08A61K31/724A61K47/08A61K47/10A61P35/00
CPCA61K31/337A61K9/08A61K47/10A61K47/6951A61P35/00A61K9/0019A61K47/32C08B37/0015A61K2300/00
Inventor W·W·赵J·K·托塔斯伊尔D·史密斯孙晓东董祥玉
Owner HUNAN JINZHUN MEDICAL TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com